AURX

Nuo Therapeutics OTCPK:AURX Stock Report

Last Price

US$0.45

Market Cap

US$18.5m

7D

-55.0%

1Y

n/a

Updated

01 Jul, 2022

Data

Company Financials
AURX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AURX Stock Overview

Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States.

Nuo Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nuo Therapeutics
Historical stock prices
Current Share PriceUS$0.45
52 Week HighUS$1.50
52 Week LowUS$0.0001
Beta-757.59
1 Month Change-55.00%
3 Month Changen/a
1 Year Changen/a
3 Year Change95.65%
5 Year Change-27.42%
Change since IPO-77.50%

Recent News & Updates

Shareholder Returns

AURXUS BiotechsUS Market
7D-55.0%0.07%-2.5%
1Yn/a-25.1%-21.2%

Return vs Industry: Insufficient data to determine how AURX performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how AURX performed against the US Market.

Price Volatility

Is AURX's price volatile compared to industry and market?
AURX volatility
AURX Average Weekly Movementn/a
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: Insufficient data to determine AURX's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine AURX's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19985David Jordenhttps://www.nuot.com

Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014.

Nuo Therapeutics Fundamentals Summary

How do Nuo Therapeutics's earnings and revenue compare to its market cap?
AURX fundamental statistics
Market CapUS$18.49m
Earnings (TTM)-US$1.26m
Revenue (TTM)n/a

0.0x

P/S Ratio

-14.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AURX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$1.26m
Earnings-US$1.26m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.031
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did AURX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AURX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AURX?

Other financial metrics that can be useful for relative valuation.

AURX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does AURX's PB Ratio compare to its peers?

AURX PB Ratio vs Peers
The above table shows the PB ratio for AURX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.8x
CRBP Corbus Pharmaceuticals Holdings
0.5x19.3%US$32.4m
APTX Aptinyx
0.5x36.2%US$37.2m
ALLR Allarity Therapeutics
0.8x14.6%US$12.1m
INFI Infinity Pharmaceuticals
5.3x-1.5%US$52.6m
AURX Nuo Therapeutics
35.1xn/aUS$18.5m

Price-To-Book vs Peers: AURX is expensive based on its Price-To-Book Ratio (35.1x) compared to the peer average (1.8x).


Price to Earnings Ratio vs Industry

How does AURX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: AURX is expensive based on its Price-To-Book Ratio (35.1x) compared to the US Biotechs industry average (1.5x)


Price to Book Ratio vs Fair Ratio

What is AURX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AURX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio35.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AURX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of AURX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AURX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AURX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AURX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Nuo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nuo Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Nuo Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Nuo Therapeutics's filings and announcements here.

Past Performance

How has Nuo Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


17.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AURX is currently unprofitable.

Growing Profit Margin: AURX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AURX is unprofitable, but has reduced losses over the past 5 years at a rate of 17.7% per year.

Accelerating Growth: Unable to compare AURX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AURX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).


Return on Equity

High ROE: AURX has a negative Return on Equity (-87.31%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Nuo Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AURX's short term assets ($962.3K) exceed its short term liabilities ($475.7K).

Long Term Liabilities: AURX's short term assets ($962.3K) exceed its long term liabilities ($55.2K).


Debt to Equity History and Analysis

Debt Level: AURX is debt free.

Reducing Debt: AURX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AURX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AURX has less than a year of cash runway if free cash flow continues to grow at historical rates of 49.7% each year.


Discover healthy companies

Dividend

What is Nuo Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AURX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AURX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AURX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AURX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AURX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.5yrs

Average management tenure


CEO

David Jorden (60 yo)

5.92yrs

Tenure

Mr. David E. Jorden, CPA has been the Chief Executive Officer and Chief Financial Officer of Nuo Therapeutics, Inc. since July 1, 2016. Mr. Jorden has been the Chief Executive Officer at Nanospectra Biosci...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AURX's management team is seasoned and experienced (6.5 years average tenure).


Board Members

Experienced Board: AURX's board of directors are seasoned and experienced ( 11.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AURX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.8%.


Top Shareholders

Company Information

Nuo Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Nuo Therapeutics, Inc.
  • Ticker: AURX
  • Exchange: OTCPK
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$18.487m
  • Shares outstanding: 41.08m
  • Website: https://www.nuot.com

Number of Employees


Location

  • Nuo Therapeutics, Inc.
  • 8285 El Rio
  • Suite 190
  • Houston
  • Texas
  • 77054
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/01 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.